This site is intended for US healthcare professionals only

Get YUTIQ
Contact Us

Administration

Learn what Makes YUTIQ Unique

YUTIQ is administered in the office setting using a specially designed applicator.

Watch the YUTIQ Administration Video

To learn about the YUTIQ administration process, you may watch the injection training video or download the brochure.

The administration video is a step-by-step guide to administering YUTIQ, including preparation, insertion procedure, and implant placement.

The YUTIQ implant is inserted into the vitreous cavity via a 25-gauge needle.  Each implant contains 0.18 mg fluocinolone acetonide (FAc) and is engineered to provide a submicogram release at an initial rate of 0.25 μg/day lasting 36 months.  Each sterile, single-use, preloaded custom applicator is packaged in a sealed tray that should be stored at room temperature between 59oF and 86oF.

Play Video

For complete information regarding YUTIQ administration, please refer to:

Injection Brochure

View PDF

Opening and handling of the YUTIQ packaging and applicator

View PDF

In-Office Injection Videos

Play Video

Dr. Michael Singer

After Dr. Singer speaks about the ideal patient, use of YUTIQ, and patient follow-up, he performs a YUTIQ injection on an actual patient in his office.

Play Video

Dr. David Callanan

Dr. Callanan, a uveitis specialist, discusses the use and potential side effects of YUTIQ as well as the ideal patient. An inset of the injection being performed accompanies this video.

Play Video

Dr. Robert Wang

Dr. Wang, a uveitis specialist, discusses how he and his team prepared to begin injecting YUTIQ in their office, including support from the company and identifying patients. He then performs the injection on an actual patient.

INDICATION AND IMPORTANT SAFETY INFORMATION

Indication

YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Important Safety Information

CONTRAINDICATIONS

  • Ocular or Periocular Infections: YUTIQ is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.

Indication

YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Important Safety Information

CONTRAINDICATIONS

  • Ocular or Periocular Infections: YUTIQ is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.
  • Hypersensitivity: YUTIQ is contraindicated in patients with known hypersensitivity to any components of this product.

 

WARNINGS AND PRECAUTIONS

  • Intravitreal Injection-related Effects: Intravitreal injections, including those with YUTIQ, have been associated with endophthalmitis, eye inflammation, increased or decreased intraocular pressure, and choroidal or retinal detachments. Hypotony has been observed within 24 hours of injection and has resolved within 2 weeks. Patients should be monitored following the intravitreal injection.
  • Steroid-related Effects: Use of corticosteroids including YUTIQ may produce posterior subcapsular cataracts, increased intraocular pressure and glaucoma. Use of corticosteroids may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection.
  • Risk of Implant Migration: Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.

 

ADVERSE REACTIONS       

  • In controlled studies, the most com­mon adverse reactions reported were cataract development and increases in intraocular pressure.

Please see full Prescribing Information at hcp.yutiq.com/pi/.

Customer Support, Product Returns or Replacements

Tel: 1-844-445-8843

Email: customerservice@alimerasciences.com

Social Media

Facebook Linkedin Instagram

AccessPlus

Tel: 1-844-445-8843

Summary Overview of AccessPlus

Adverse Event Reporting
or Medical Inquiry

Tel: 1-844-445-8843

Fax: 1-678-990-5744

Email: pvalimerasciences@alimerasciences.com

Prescribing Information
Terms & Conditions
Privacy Policy
Alimera Sciences, Inc. Website

This site is intended for US residents only. YUTIQ is a registered trademark of Alimera Sciences, Inc.
CONTINUOUS MICRODOSING and the CONTINUOUS MICRODOSING symbol are trademarks of Alimera Sciences, Inc.

Copyright © 2024 Alimera Sciences, Inc. All rights reserved.

 1-844-445-8843. US-YTQ-MMM-0032

Link to Healthcare Professionals Site
The information contained on this site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
Close
OK

References

  1. YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg full U.S. Prescribing Information. Alimera Sciences, Inc. June 2023.

References

  1. Data on file. Alimera Sciences, Inc. MI-DOF-YUT-006
  2. Data on file. Alimera Sciences, Inc. MI-DOF-YUT-001
  3. Data on file. Alimera Sciences, Inc. MI-DOF-YUT-003
  4. YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg full U.S. Prescribing Information. Alimera Sciences, Inc. June 2023.
  5. Data on file. Alimera Sciences, Inc. MI-DOF-YUT-002.

References

  1. YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg full U.S. Prescribing Information. Alimera Sciences, Inc. June 2023
  2. Thorne JE, Suhler E, Skup M, et al. Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis. JAMA Ophthalmol. 2016;134(11):1237-1245. 2016;134:1237-1245.
  3. Chorich LJ III, et a;. Diagnosis and Treatment of Uveitis. 2013.

Study Design

  1. Study design: The efficacy of YUTIQ was assessed in 2 randomized, multicenter, sham-controlled, double-masked, phase 3 studies in adult patients [N=282] with noninfectious uveitis affecting the posterior segment of the eye. The primary endpoint in both studies was the proportion of patients who experienced recurrence of uveitis in the study eye within 6 months of follow-up; recurrence was also assessed at 12 months. Recurrence was defined as either deterioration in visual acuity, vitreous haze attributable to noninfectious uveitis, or the use of confounding medications.1
Get
YUTIQ
Contact
Us

References

  1. YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg full U.S. Prescribing Information. Alimera Sciences, Inc. June 2023.
  2. Data on file. Alimera Sciences, Inc. MI-DOF-YUT-007
  3. Data on file. Alimera Sciences, Inc. MI-DOF-YUT-008